{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65","upperLimit":"91","value":"80"},{"groupId":"OG001","lowerLimit":"5","upperLimit":"36","value":"16"},{"groupId":"OG002","lowerLimit":"55","upperLimit":"83","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"}],"units":"Participants"}],"description":"Disease Control Rate (DCR) is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions, progressive disease (PD) is \\>20% increase in sum of diameters of target lesions, stable disease (SD) is \\<30% decrease or \\<20% increase in sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG000","title":"Cohort A: MSI Positive Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG001","title":"Cohort B: MSI Negative Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG002","title":"Cohort C: MSI Positive Non-Colorectal Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 months","title":"Disease Control Rate in MSI Positive and Negative Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}